Simplify Life®
with Omnipod® 5
Why Omnipod 5?
- Australia’s first and only tubeless, waterproof† automated insulin delivery system compatible with leading sensor brands*
- Automatically adjusts insulin every five minutes¹,²
- Delivered more than 80% time in range with optimised settings3.
Already a Podder®? Find everything you need in one place, in your personal user portal.
What is Omnipod®?
Omnipod is a range of tubeless insulin delivery systems designed for people living with diabetes.
Each waterproof†, wearable Pod continuously delivers personalised doses of insulin for up to three days (72 hours).
With no multiple daily injections to interrupt your daily activities, and no tubes to cause unwanted tangles, it’s time to discover the freedom of Omnipod.
Meet our tubeless, wearable Omnipod lineup
Omnipod 5 Automated Insulin Delivery System
Experience the freedom of automated insulin delivery and improved time in range1,2 with compatibility across leading sensor brands.
Omnipod DASH® Insulin Management System
You’re in control with the Omnipod DASH® Personal Diabetes Manager. Discover discreet, precise insulin dosing and customisable programmes designed to fit around your lifestyle.
Here’s what our Podders® have to say about Omnipod…
My life is easier.
Joshua P
Podder® since 2025
It has changed my life. I have confidence and my self-esteem is back now.
Monique R
Podder® since 2025
All round for the whole family – it was like a weight had been lifted off of our shoulders.
Gill, Mother of Ella K
Podder ® since 2025
Curious what life could feel like with Omnipod 5?
Whether you want a hands-on trial, expert guidance, or a live walkthrough, we’re here to help you get started with confidence.
* [Requires compatible sensors. Bolus for meals and corrections are still needed.]
† The Pod has an IP28 rating for up to 7.6 metres (25 feet) for 60 minutes. The Omnipod 5 Controller is not waterproof. Please see sensor manufacturer user guide for sensor waterproof rating‡ Finger pricks required for diabetes treatment decisions if symptoms or expectations do not match readings.
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001. Mean HbA1c: ST vs. Omnipod 5 use in adults/adolescents (14-70 yrs) and children (6-13.9 yrs), respectively (7.16% vs 6.78% or 55 mmol/mol vs. 51 mmol/mol, P<0.0001; 7.67% vs 6.99% or 60mmol/mol vs 53 mmol/mol), P<0.0001. Mean time >10.0 mmol/L or >180mg/dL (12AM-<6AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 32.1% vs. 20.7%; 42.2% vs 20.7%, P<0.0001, respectively. Mean time >10.0 mmol/L or >180mg/dL (6AM-<12AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 32.6% vs. 26.1%; 46.4% vs 33.4%, P<0.0001, respectively. Mean time <3.9 mmol/L or <70 mg/dL (12AM-<6AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 3.64% vs. 1.17%, P<0.0001; 2.51% vs. 1.78, P=0.0456, respectively. Mean time <3.9 mmol/L or <70 mg/dL (6AM-<12AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 2.64% vs. 1.37%, P<0.0001; 2.13% vs. 1.98%, P=0.2545, respectively.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5 system. Mean HbA1c as measured in very young children, ST vs. Omnipod 5 use:7.4% vs 6.9% or 57 mmol/ml vs. 53 mmol/mol; (P<0.0001). Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001. Mean time >10.0 mmol/L or >180mg/dL (12AM-<6AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 38.4% vs. 16.9%, P<0.0001, respectively. Mean time >10.0 mmol/L or >180mg/dL (6AM-<12AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.7% vs. 33.7%, P<0.0001, respectively. Mean time <3.9 mmol/L or <70 mg/dL (12AM-<6AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 3.41% vs. 2.13%, P=0.0185. Mean time <3.9 mmol/L or <70 mg/dL (6AM-<12AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 3.44% vs. 2.57%, P=0.0799.
3. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.
